Inhibition of Candida albicans biofilm formation by antimycotics released from modified polydimethyl siloxane.
Unlike various disinfectants, antifungals have not been commonly incorporated so far in medical devices, such as catheters or prostheses, to prevent biofilm formation by Candida spp. In the present study, five antimycotics were added to polydimethyl siloxane (PDMS) disks via admixture (nystatin) or impregnation (trimethylsilyl-nystatin (TMS-nystatin), miconazole, tea tree oil (TTO), zinc pyrithione). Nystatin-medicated PDMS disks exhibited a concentration-dependent inhibitory effect on biofilm formation in a microtiter plate (MTP) but not in a Modified Robbins Device (MRD). This observation, together with HPLC data and agar diffusion tests, indicates that a small fraction of free nystatin is released, which kills Candida albicans cells in the limited volume of a MTP well. In contrast, biofilm inhibition amounted to more than one log unit in the MRD on disks impregnated with miconazole, TTO, and zinc pyrithione. It is hypothesized that the reduction in biofilm formation by these compounds in a flow system occurs through a contact-dependent effect.
De Prijck
Kristof
K
Laboratory of Pharmaceutical Microbiology, Ghent University, Harelbekestraat 72, Ghent, 9000, Belgium.
De Smet
Nele
N
Honraet
Kris
K
Christiaen
Steven
S
Coenye
Tom
T
Schacht
Etienne
E
Nelis
Hans J
HJ
D000935:Antifungal Agents / Q000493:pharmacokinetics / Q000494:pharmacology*; D018441:Biofilms / Q000187:drug effects*; D002176:Candida albicans / Q000187:drug effects*; D015169:Colony Count, Microbial; D004129:Dimethylpolysiloxanes / Q000378:metabolism*; D004337:Drug Carriers / Q000378:metabolism*; D006801:Humans
D000935:Antifungal Agents; D004129:Dimethylpolysiloxanes; D004337:Drug Carriers; C013830:baysilon